Core Insights - Scancell Holdings plc has provided a business update and unaudited financial results for the six-month period ending October 31, 2025, highlighting advancements in its cancer immunotherapy products and financial performance [1]. Product Development - The lead product, iSCIB1+, demonstrated a 74% progression-free survival (PFS) at 16 months in a Phase 2 trial for advanced melanoma, showing a 24% improvement over standard care [6][16]. - The FDA has cleared an Investigational New Drug (IND) application for a Phase 3 trial of iSCIB1+ in advanced melanoma, with PFS as the primary endpoint [6][12]. - Modi-1, another candidate, is showing promise in a Phase 2 study for squamous cell cancer of the head and neck and renal cell carcinoma, with data readouts expected in H1 2026 [6][20]. - GlyMab Therapeutics Limited has been established as a subsidiary to focus on antibody assets, with positive scientific advice received for the lead antibody product, SC134, targeting small cell lung cancer [6][21]. Financial Performance - The operating loss for the six months ended October 31, 2025, was £8.9 million, an improvement from a loss of £10.5 million in the same period in 2024 [5][23]. - Research and development expenditure decreased to £6.1 million from £8.0 million in 2024, primarily due to reduced manufacturing costs [24]. - The cash balance at October 31, 2025, was £8.6 million, down from £16.9 million at April 30, 2025, with a cash runway extending to H2 2026 [10][26]. Strategic Outlook - The company plans to initiate a global Phase 3 registrational study for iSCIB1+ in 2026, with potential commercialization anticipated in 2029 [6][7]. - Continued discussions for partnerships regarding iSCIB1+ and the ImmunoBody platform are ongoing, with a focus on optimizing shareholder value [8][12]. - The company is exploring further financing options to support the Phase 3 trial and other development initiatives [8][12].

Core Insights - AC Immune SA is set to present its precision medicine pipeline at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025) in Vienna, Austria, from April 1 to 5, 2025, focusing on active immunotherapies for neurodegenerative diseases [1][4] Group 1: Upcoming Presentations - The company will host an industry symposium on April 2, 2025, featuring key opinion leaders discussing advances in clinical development of active immunotherapies [2] - Presentations will cover topics such as disease modification in Parkinson's disease, targeting alpha-synuclein, and precision prevention strategies for Alzheimer's disease [2][3] - The symposium will include a Q&A session and a replay will be available on AC Immune's website [2] Group 2: Research and Development Highlights - AC Immune's pipeline includes Morphomer® small molecules targeting Tau for Alzheimer's disease treatment, with a presentation scheduled for April 5, 2025 [3] - The company is developing Morphomer-antibody drug conjugates, a new class of drugs for neurodegenerative diseases [3] - Research on therapeutic small molecules targeting alpha-synuclein aggregation will also be presented [3] Group 3: Company Overview - AC Immune is a clinical-stage biopharmaceutical company focused on precision prevention for neurodegenerative diseases, leveraging its two technology platforms, SupraAntigen® and Morphomer® [6] - The company has a diversified pipeline featuring candidates in Phase 2 and Phase 3 development, with significant strategic partnerships leading to over $4.5 billion in potential milestone payments and royalties [6]